Abstracts tagged "classification criteria and cross-sectional studies"

Abstract Number: 1244 • 2016 ACR/ARHP Annual Meeting
Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies
Lorenzo Beretta¹, Laurence Laigle², Ricard Cervera³, Alessandro Santaniello¹, Julien Hervouet⁴, Chris Chamberlain⁵, Jacqueline Marovac⁵, Maria Juárez⁶, Javier Martín⁷, Sambasiva Rao⁸, Jacques-Olivier Pers⁹, Johan Frostegård¹⁰, Jerome Wojcik¹¹, Bernard R. Lauwerys¹² and Marta E. Alarcon Riquelme^13,14, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Institut de Recherches Internationales Servier, SURESNES CEDEX, France, ³Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Institut de Recherches Internationales Servier, Suresnes cedex, France, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB, Slough, United Kingdom, ⁷Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ⁸Sanofi Genzyme, Boston, MA, ⁹INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, ¹⁰Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹QuartzBIO, SA, Geneva, Switzerland, ¹²Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹³Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic autoimmune diseases (SADs) are heterogeneous conditions with peculiar characteristics that share several clinical features. It is suspected that SADs share similar molecular abnormalities,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].